Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Miguel Ángel Molina‐Vila"'
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/a71637a762b04bf3be25a17680e25ef7
Autor:
Silvia García-Roman, Mónica Garzón-Ibáñez, Jordi Bertrán-Alamillo, Núria Jordana-Ariza, Ana Giménez-Capitán, Beatriz García-Peláez, Marta Vives-Usano, Jordi Codony-Servat, Erik d'Hondt, Rafael Rosell, Miguel Ángel Molina-Vila
Publikováno v:
Translational Oncology, Vol 40, Iss , Pp 101878- (2024)
Background: The EGFR pathway is involved in intrinsic and acquired resistance to a wide variety of targeted therapies in cancer. Vaccination represents an alternative to the administration of anti-EGFR monoclonal antibodies, such as cetuximab or pani
Externí odkaz:
https://doaj.org/article/fc3b1c5adf764070ae7e5f5cd5f1ee1a
Autor:
Carlos Pedraz-Valdunciel, PhD, Masaoki Ito, MD, Stavros Giannoukakos, PhD student, Ana Giménez-Capitán, MSc, Miguel Ángel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100604- (2023)
Introduction: As recently evidenced by the ADAURA trial, most patients with stages IB to IIIA of resected EGFR-mutant lung adenocarcinoma benefit from osimertinib as adjuvant therapy. Nevertheless, predictive markers of response and recurrence are st
Externí odkaz:
https://doaj.org/article/d9bf3f77370d44da9f2f5fc06d7d9205
Autor:
Nadine Reischmann, Carolin Schmelas, Miguel Ángel Molina-Vila, Núria Jordana-Ariza, Daniel Kuntze, Silvia García-Roman, Manon A. Simard, Doreen Musch, Christina Esdar, Joachim Albers, Niki Karachaliou
Publikováno v:
iScience, Vol 26, Iss 7, Pp 107006- (2023)
Summary: This study evaluates the efficacy of combining targeted therapies with MET or SHP2 inhibitors to overcome MET-mediated resistance in different NSCLC subtypes. A prevalence study was conducted for MET amplification and overexpression in sampl
Externí odkaz:
https://doaj.org/article/212794a83ace4b01a781beca9b628143
Autor:
Atocha Romero, Eloisa Jantus‐Lewintre, Beatriz García‐Peláez, Ana Royuela, Amelia Insa, Patricia Cruz, Ana Collazo, Javier Pérez Altozano, Oscar Juan Vidal, Pilar Diz, Manuel Cobo, Berta Hernández, Sergio Vázquez Estevez, Gretel Benítez, Maria Guirado, Margarita Majem, Reyes Bernabé, Ana Laura Ortega, Ana Blasco, Joaquim Bosch‐Barrera, Jose M. Jurado, Jorge García González, Santiago Viteri, Carlos Garcia Giron, Bartomeu Massutí, Ana Lopez Martín, Alejandro Rodriguez‐Festa, Silvia Calabuig‐Fariñas, Miguel Ángel Molina‐Vila, Mariano Provencio
Publikováno v:
Molecular Oncology, Vol 15, Iss 1, Pp 43-56 (2021)
Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%. Prospective studies evaluating agreement and sources for discordant results remain lacking. Herein, seven methodolo
Externí odkaz:
https://doaj.org/article/fee84be40c92476693b579001138154a
Autor:
Carlos Pedraz-Valdunciel, Stavros Giannoukakos, Ana Giménez-Capitán, Diogo Fortunato, Martyna Filipska, Jordi Bertran-Alamillo, Jillian W. P. Bracht, Ana Drozdowskyj, Joselyn Valarezo, Natasa Zarovni, Alberto Fernández-Hilario, Michael Hackenberg, Andrés Aguilar-Hernández, Miguel Ángel Molina-Vila, Rafael Rosell
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2034 (2022)
Background: The analysis of liquid biopsies brings new opportunities in the precision oncology field. Under this context, extracellular vesicle circular RNAs (EV-circRNAs) have gained interest as biomarkers for lung cancer (LC) detection. However, st
Externí odkaz:
https://doaj.org/article/4b768aff04134ca0a6c572a1e40f25df
Autor:
Julia Elzanowska, Laura Berrocal, Beatriz García-Peláez, Marta Vives-Usano, Beatriz Passos Sebo, Joana Maia, Silvia Batista, Jaakko Teppo, Markku Varjosalo, Maria Carolina Strano Moraes, Miguel Ángel Molina-Vila, Bruno Costa-Silva
Publikováno v:
Cancers, Vol 14, Iss 13, p 3258 (2022)
(1) Background: Extracellular vesicles (EVs) have emerged as crucial players in the communication between cells in both physiological and pathological scenarios. The functions of EVs are strongly determined by their molecular content, which includes
Externí odkaz:
https://doaj.org/article/7fd3a23597ab44da87f8e0575995c12d
Autor:
Jordi Codony-Servat, Silvia García-Roman, Miguel Ángel Molina-Vila, Jordi Bertran-Alamillo, Santiago Viteri, Erik d'Hondt, Rafael Rosell
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100887- (2021)
Advanced NSCLC patients harboring EML4-ALK and CCDC6-RET rearrangements derive benefit from treatment with ALK and RET TKIs but not immune checkpoint inhibitors. New immunotherapeutic approaches, such as immunization against growth factors, can be of
Externí odkaz:
https://doaj.org/article/ffe440135f614a88ae6f23e8d7bf0ef5
Autor:
Roberto Serna-Blasco, Estela Sánchez-Herrero, María Berrocal Renedo, Silvia Calabuig-Fariñas, Miguel Ángel Molina-Vila, Mariano Provencio, Atocha Romero
Publikováno v:
Biology, Vol 10, Iss 10, p 954 (2021)
Next-generation sequencing (NGS) has enabled a deeper knowledge of the molecular landscape in non-small cell lung cancer (NSCLC), identifying a growing number of targetable molecular alterations in key genes. However, NGS profiling of liquid biopsies
Externí odkaz:
https://doaj.org/article/2a22f2dc30084a86919d5d3185d53a53
Autor:
Elba Marin, Cristina Teixido, Elena Carmona-Rocha, Roxana Reyes, Ainara Arcocha, Nuria Viñolas, MªCarmen Rodríguez-Mues, Carlos Cabrera, Marcelo Sánchez, Ivan Vollmer, Sergi Castillo, Silvia Muñoz, Ivana G. Sullivan, Adela Rodriguez, Mireia Garcia, Silvia Alos, Pedro Jares, Antonio Martinez, Aleix Prat, Miguel Ángel Molina-Vila, Noemi Reguart
Publikováno v:
Cancers, Vol 12, Iss 5, p 1124 (2020)
Personalized medicine is nowadays a paradigm in lung cancer management, offering important benefits to patients. This study aimed to test the feasibility and utility of embedding two multiplexed genomic platforms as the routine workup of advanced non
Externí odkaz:
https://doaj.org/article/b747b36202ad4acb92e8e842901640ee